Advanced search
Publication Cover
Journal of Chemotherapy Volume 31, 2019 - Issue 7-8
Submit an article Journal homepage
161
Views
3
CrossRef citations to date
0
Altmetric
Case Reports

Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma

Aman VermaDepartment of Internal Medicine, Veterans Administration Health Care System, Minneapolis, MN, USA; View further author information
,
Michael MbughuniPathology and Laboratory Medicine, Veterans Administration Health Care System, Minneapolis, MN, USA; View further author information
,
Evan MariashHematology Oncology, Veterans Administration Health Care System, Minneapolis, MN, USAView further author information
&
Hector MesaPathology and Laboratory Medicine, Veterans Administration Health Care System, Minneapolis, MN, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1833-4642View further author information
ORCID Icon
Pages 428-431 | Received 26 Jun 2019, Accepted 29 Oct 2019, Published online: 18 Nov 2019

References

  • Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks R, et al. Ibrutinib plus Venetoclax for the treatment of mantle-cell ymphoma. N Engl J Med. 2018;378:1211–1223.
  • Meng QH, Wagar EA. Pseudohyperkalemia: a new twist on an old phenomenon. Crit Rev Clin Lab Sci. 2015;52:45–55.
  • Dimeski G, Bird R. Hyperleukocytosis: pseudohyperkalemia and other biochemical abnormalities in hyperleukocytosis. Clin Chem Lab Med. 2009;47:880–881.
  • Rifkin SI. Case Report: Pseudohyperkalemia in patients with chronic lymphocytic leukemia. Int J Nephrol. 2011;2011:759749. doi:10.4061/2011/759749.
  • Katkish L, Rector T, Ishani A, Gupta P. Incidence and severity of pseudohyperkalemia in chronic lymphocytic leukemia: a longitudinal analysis. Leuk Lymphoma. 2016;57:1952–1955.
  • Titus-Rains KS, Brown JN, Hammond JM. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: a case series and review of the literature. J Oncol Pharm Pract. 2018; 24:544–549.
  • Herman SE, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–2196.
  • Cheson BD, Heitner Enschede S, Cerri E, Desai M, Potluri J, Lamanna N, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist. 2017;22:1283–1291.
  • Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132:1568–1572.
  • Salem AH, Agarwal SK, Dunbar M, Heitner-Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57:484–492.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.